Comparative Weight Change With Initiation and Adherence to Common Medications for Type 2 Diabetes

Authors:

Abstract
Objective: This study aimed to estimate population‐level effects on weight change of initiating/adhering to additional glucose‐lowering medications in adults with type 2 diabetes prescribed metformin. Methods: We conducted a target trial using electronic health record data from 22,601 patients (age 20 to < 80 years) prescribed metformin to determine initiation/adherence to dipeptidyl peptidase IV (DPP4) inhibitors, glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors, long‐acting insulin, or sulfonylureas. Inverse probability weighting of marginal structural models with standardization by baseline covariates was used to estimate population‐level effects of initiating/adhering to different medications on average 24‐month weight change. Results: At 24 months, a mean −5.15 kg (95% CI −10.6, −1.36) and −6.71 kg (95% CI −8.38, −4.34) weight loss would be observed for initiation/adherence to GLP‐1RAs and SGLT‐2s respectively. At 6 months, weight loss for DPP4s would be observed (−0.89 kg, 95% CI −1.41, −0.32) though not at 12 or 24 months. Glimepiride would be associated with weight gain at 6 and 12 months (0.88 kg, 95% CI 0.44, 1.22; 1.01 kg, 95% CI 0.32, 1.51) but not at 24 months. Conclusions: Initiation/adherence to GLP‐1RAs and SGLT‐2s over 24 months could result in average weight losses of 5.15 kg and 6.71 kg, respectively.
Funding Information
  • Agency for Healthcare Research and Quality (T32HS026122)
  • National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK120598)
  • National Center for Advancing Translational Sciences (5KL2TR002245)

This publication has 38 references indexed in Scilit: